Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques

Diogo M. Magnani, Thomas F. Rogers, Nathan Beutler, Michael J. Ricciardi, Varian K. Bailey, Lucas Gonzalez-Nieto, Bryan Briney, Devin Sok, Khoa Le, Alexander Strube, Martin J. Gutman, Nuria Pedreno-Lopez, Nathan D. Grubaugh, Cassia G.T. Silveira, Helen S. Maxwell, Aline Domingues, Mauricio A. Martins, David E. Lee, Erica E. Okwuazi, Sherrie JeanElizabeth A. Strobert, Ann Chahroudi, Guido Silvestri, Thomas H. Vanderford, Esper G. Kallas, Ronald C. Desrosiers, Myrna C. Bonaldo, Stephen S. Whitehead, Dennis R. Burton, David I. Watkins

Research output: Contribution to journalArticlepeer-review

54 Scopus citations


Therapies to prevent maternal Zika virus (ZIKV) infection and its subsequent fetal developmental complications are urgently required. We isolated three potent ZIKV-neutralizing monoclonal antibodies (nmAbs) from the plasmablasts of a ZIKV-infected patient-SMZAb1, SMZAb2, and SMZAb5-directed against two different domains of the virus. We engineered these nmAbs with Fc LALA mutations that abrogate Fcg receptor binding, thus eliminating potential therapy-mediated antibody-dependent enhancement. We administered a cocktail of these three nmAbs to nonhuman primates 1 day before challenge with ZIKV and demonstrated that the nmAbs completely prevented viremia in serum after challenge. Given that numerous antibodies have exceptional safety profiles in humans, the cocktail described here could be rapidly developed to protect uninfected pregnant women and their fetuses.

Original languageEnglish (US)
Article numberaan8184
JournalScience Translational Medicine
Issue number410
StatePublished - Oct 4 2017

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques'. Together they form a unique fingerprint.

Cite this